Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 5.

Pagani, O; Klingbiel, D; Ruhstaller, T; Nolè, F; Eppenberger, S; Oehlschlegel, C; Bernhard, J; Brauchli, P; Hess, D; Mamot, C; Munzone, E; Pestalozzi, B; Rabaglio, M; Aebi, S; Ribi, K; Rochlitz, C; Rothgiesser, K; Thürlimann, B; Moos, R von; Zaman, K; Goldhirsch, A; Swiss Group for Clinical Cancer Research (SAKK) (2017). Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized Phase III trial SAKK 22/99. Annals of Oncology, 28(2):305-312.

Eichholzer, M; Schmid, S M; Bovey, F; Jordan, P; Rohrmann, S; Huang, D J; Rochlitz, C; Güth, U (2012). Impact of overweight and obesity on postmenopausal breast cancer: analysis of 20-year data from Switzerland. Archives of Gynecology and Obstetrics, 285(3):797-803.

Rochlitz, C; Ruhstaller, T; Lerch, S; Spirig, C; Huober, J; Suter, T; Buhlmann, M; Fehr, M; Schonenberger, A; von Moos, R; Winterhalder, R; Rauch, D; Muller, A; Mannhart-Harms, M; Herrmann, R; Cliffe, B; Mayer, M; Zaman, K (2011). Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06). Annals of Oncology, 22(1):80-85.

Rochlitz, C; Senn, H-J; Betticher, D; Helbling, D; von Moos, R; Pestalozzi, B; Thürlimann, B; Uebelhart, D; Aapro, M (2010). Der Einsatz von Bisphosphonaten bei der Behandlung solider Tumoren. Swiss Medical Forum, 10(34):562-564.

Dummer, R; Rochlitz, C; Velu, T; Acres, B; Limacher, J M; Bleuzen, P; Lacoste, G; Slos, P; Romero, P; Urosevic, M (2008). Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma. Molecular Therapy, 16(5):985-994.

This list was generated on Thu Jun 20 05:01:59 2019 CEST.